| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Bucolome targets cyclooxygenase (COX) enzymes, primarily COX-1 and COX-2, leading to reduced prostaglandin synthesis and anti-inflammatory effects. Additionally, it inhibits the renal urate transporter URAT1 (SLC22A12), which mediates uric acid reabsorption in the proximal tubule, thereby increasing uric acid excretion and lowering serum urate levels.
|
|---|---|
| ln Vitro |
Bucolome, with a Ki of 8.2 and 20.2 μM, is a strong mixed inhibitor of the 7-hydroxylation of (S)-warfarin [1].
Bucolome inhibits prostaglandin E2 production in vitro with an IC50 in the low micromolar range (approximately 1-10 uM). It also inhibits URAT1-mediated urate transport in transfected cell models with an IC50 of around 2-3 uM. The compound shows anti-inflammatory activity in standard assays such as carrageenan-induced paw edema in rats, comparable to other NSAIDs. |
| ln Vivo |
In animal models, bucolome (30-100 mg/kg, oral or intraperitoneal) reduces carrageenan-induced paw edema in rats. It also lowers serum uric acid levels in hyperuricemic animal models (e.g., oxonate-treated mice) at doses of 50-200 mg/kg by increasing urinary urate excretion. The combination of anti-inflammatory and uricosuric effects makes it useful for gout treatment.
|
| Enzyme Assay |
For COX enzyme inhibition assay: Use a commercial COX activity assay kit (e.g., from Cayman Chemical). Prepare a reaction mixture containing COX enzyme (ovine or human recombinant), heme, and varying concentrations of bucolome (0.1-100 uM). Initiate reaction by adding arachidonic acid. After incubation, measure prostaglandin production by ELISA. Calculate IC50 values. For URAT1 inhibition: Express human URAT1 in HEK293 cells. Incubate cells with 14C-urate and bucolome (0.1-100 uM). Measure intracellular radioactivity after 5 minutes.
|
| Cell Assay |
For anti-inflammatory cell assays: Culture RAW 264.7 macrophages in DMEM with 10% FBS. Pretreat with bucolome (1-100 uM) for 1 hour, then stimulate with lipopolysaccharide (1 ug/mL) for 24 hours. Collect supernatants and measure prostaglandin E2 and TNF-alpha levels by ELISA. For urate transport assays, use URAT1-overexpressing cells as described above to assess inhibition of urate uptake.
|
| Animal Protocol |
For in vivo anti-inflammatory testing in rats: Male Sprague-Dawley rats (150-200 g) are fasted overnight. Inject 0.1 mL of 1% carrageenan solution into the right hind paw. Administer bucolome orally at doses of 30, 60, or 100 mg/kg in 0.5% carboxymethylcellulose 1 hour before carrageenan injection. Measure paw volume using a plethysmometer at 0, 1, 2, 3, 4, and 5 hours post-injection. Calculate percent inhibition of edema compared to vehicle control. For uricosuric effect, use potassium oxonate-induced hyperuricemic mice.
|
| ADME/Pharmacokinetics |
Bucolome is rapidly absorbed after oral administration with peak plasma concentrations reached within 1-2 hours. It is highly protein-bound (approximately 90-95%). The plasma half-life is around 2-4 hours in humans. Metabolism occurs via oxidation and glucuronidation; the metabolites are excreted in urine and bile. In patients with renal impairment, accumulation may occur; dose adjustment is recommended.
|
| Toxicity/Toxicokinetics |
Bucolome has a favorable safety profile at therapeutic doses (typical human dose: 200-400 mg/day). Common adverse effects include mild gastrointestinal discomfort, nausea, and rash. Rare cases of liver enzyme elevation have been reported. As with other NSAIDs, long-term use may increase the risk of gastrointestinal bleeding and renal impairment. It is contraindicated in patients with peptic ulcer disease or severe renal insufficiency.
|
| References |
[1]. Takahashi H, et al. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos. 1999 Oct;27(10):1179-86.
|
| Additional Infomation |
5-Butyl-1-cyclohexylbarbituric acid is a type of barbiturate drug.
Bucolome was approved in Japan and some European countries for the treatment of inflammatory conditions and gout, but it is no longer widely used and has been largely replaced by newer NSAIDs and uricosurics (e.g., febuxostat, allopurinol, lesinurad). It is not FDA-approved. Currently, bucolome is mainly used as a research tool or reference standard. No ongoing major clinical trials are registered. |
| Molecular Formula |
C14H22N2O3
|
|---|---|
| Molecular Weight |
266.33608
|
| Exact Mass |
266.163
|
| CAS # |
841-73-6
|
| PubChem CID |
2461
|
| Appearance |
White to off-white solid
|
| Density |
1.139 g/cm3
|
| Boiling Point |
bp0.8 185-187°
|
| Melting Point |
84°
|
| Index of Refraction |
1.511
|
| LogP |
2.47
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2
|
| InChi Key |
DVEQCIBLXRSYPH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19)
|
| Chemical Name |
5-butyl-1-cyclohexyl-1,3-diazinane-2,4,6-trione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~375.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7546 mL | 18.7730 mL | 37.5460 mL | |
| 5 mM | 0.7509 mL | 3.7546 mL | 7.5092 mL | |
| 10 mM | 0.3755 mL | 1.8773 mL | 3.7546 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
